In order to accelerate research and development, as well as accelerate market development, many pharmaceutical companies are obtaining financial support
through financing.
It is reported that in the past week (December 28, 2022-January 3, 2023), a large number of enterprises have announced the completion of financing
.
It is worth noting that many of these enterprises have raised funds of 100 million yuan
.
Xinkainuo Medical completed a financing of 100 million yuan
On December 30, Xinkainuo Medical Company announced the completion of a financing of 100 million yuan, jointly invested
by Zhangjiang Hi-Tech, Pudong Capital, Zhangjiang Haoheng and Suxin Venture Capital.
This round of financing will be used to accelerate the development of domestic and foreign markets and regional cultivation, while accelerating the layout
of new neurointerventional and peripheral interventional products.
According to the data, Xinkainuo Medical Technology (Shanghai) Co.
, Ltd.
, established in August 2014, is a high-tech enterprise focusing on independent research and development, manufacturing high-end implantable/interventional medical devices for nerves and peripheral vessels, and is committed to providing doctors and patients with high-quality and complete vascular implantation/interventional device solutions
.
Core Medical completed hundreds of millions of yuan in Series C financing
News on December 30, Shenzhen Core Medical Technology Co.
, Ltd.
(hereinafter referred to as "Core Medical") has completed hundreds of millions of yuan in Series C financing, which is jointly invested by Yuan Henry Zhen Capital, Cornerstone Capital, Salubris Medical Devices, Nanshan Zhan New Investment, Beihang Capital, etc.
, and the existing shareholders Lianxin Capital and Hillhouse Venture Capital continue to invest
more.
This round of financing will be mainly used to accelerate the R&D, clinical and commercialization layout of the product line, and build an innovative active implant intervention platform
.
Founded in 2016, Core Medical is committed to providing professional mechanical circulation support comprehensive solutions
for heart failure patients.
At present, it has more than 200 independent research and development patent technology accumulation and five basic R & D technology platforms in the world, and has strong R & D strength
.
Lingfu Biotech completed the A1 round of financing of RMB 170 million
On December 29, Jinglingfu Biotechnology Co.
, Ltd.
(hereinafter referred to as "Lingfu Biotechnology") completed the A1 round of financing of 170 million yuan, with investment institutions including Hainan Rongzhi Fund, Sanya Yazhou Bay Venture Capital, Heyu Capital, Legend Capital, Puhua Capital, Saifu Pharmaceutical and the founding team
.
It is reported that Lingfu Biotech is committed to building a scientific research service provider
that integrates the whole industry chain of experimental model resources, the whole industry chain of experimental model technology and high value-added innovative scientific research services.
The company's financing purpose will be mainly used for the layout of non-human primate resource bases and the construction of experimental facilities, continue to improve the layout of high-quality experimental animal resource industry chain, and form a complete closed loop
of NHP resources and service capabilities of spiritual organisms.
It is worth noting that previously, the company has completed tens of millions of yuan in angel rounds and more than 200 million yuan in pre-A round financing
.
Majing Gene completed a series C financing of hundreds of millions of yuan
News on December 29, Guangzhou Maijing Gene Medical Technology Co.
, Ltd.
(hereinafter referred to as "Maijing Gene") announced the completion of hundreds of millions of yuan in Series C financing
.
This round of financing was led by Yifeng Capital, followed by Angu Fuge, Jiuyou Capital, Renchi Capital and Hongtu Runda
.
The funds raised will be used for R&D investment and IVD product registration
.
It is understood that Maijing Gene was established in 2015, headquartered in Guangzhou International Bio Island, and set up branches
in East China, Central China and North China.
Since its establishment, the company has been adhering to the customer-oriented service concept, committed to the overall solution in the field of tumor precision medicine, and has developed into a high-tech enterprise
integrating R&D, production, sales and service.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
